Pictured: Illustration of CRISPR-Cas9 editing DNA / iStock, Artur Plawgo
Currently, there are no gene editing–based treatments on the market, but the technology continues its march toward potential FDA approval, with several products in mid-and late-stage trials. As these programs mature, 2023 could be a pivotal year for companies in the space. Here are some highlights to look forward to as the year progresses.
CRISPR Therapeutics/Vertex Pharmaceuticals.
Comments are closed.